<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sucralfate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sucralfate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sucralfate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11055" href="/d/html/11055.html" rel="external">see "Sucralfate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12811" href="/d/html/12811.html" rel="external">see "Sucralfate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57397476"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Carafate</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868303"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Sucralfate;</li>
<li>Cytogard;</li>
<li>Sulcrate;</li>
<li>Sulcrate Plus;</li>
<li>TEVA-Sucralfate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F223566"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gastrointestinal Agent, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F223523"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="326a86c2-20b8-4117-82b9-2b7b1e9d18d2">Duodenal ulcer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duodenal ulcer:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Active duodenal ulcer: Suspension, tablet: Initial: 1 g four times daily for 4 to 8 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance therapy: Tablet: 1 g twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8ccfc5b-519e-4e5b-ac14-b953aecc2483">Gastroesophageal reflux disease in pregnancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease in pregnancy (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For persistent symptoms despite nonpharmacologic measures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16225482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16225482'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>1 g three times daily; if symptoms do not improve, additional or alternative therapy should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34807007','lexi-content-ref-Ranchet.1','lexi-content-ref-16225482','lexi-content-ref-31950535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34807007','lexi-content-ref-Ranchet.1','lexi-content-ref-16225482','lexi-content-ref-31950535'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="621a803a-f8f1-4160-b015-a8a460bc49da">Marginal (anastomotic) ulceration after bariatric surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Marginal (anastomotic) ulceration after bariatric surgery (adjunctive agent) (off-label use): Oral: </b>Suspension: 1 g four times daily in combination with twice-daily proton pump inhibitor; institutional guidelines vary; refer to center-specific protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29556889','lexi-content-ref-16925380','lexi-content-ref-28809386','lexi-content-ref-24347350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29556889','lexi-content-ref-16925380','lexi-content-ref-28809386','lexi-content-ref-24347350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72445339-9a73-4453-a8ad-9d389e98acc6">Oral ulcers, simple recurrent stomatitis and ulcers associated with Behçet disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral ulcers, simple recurrent stomatitis and ulcers associated with Behçet disease (alternative agent) (adjunctive agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider for use in patients with persistent symptoms despite other therapies; may be used in combination with other topical therapies (eg, steroid, antibiotic, anesthetic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brice.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brice.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Suspension<b>: </b>1 g for 1 to 2 minutes after routine mouth care 4 times daily; alternatively, suspension may be applied directly to the oral ulcer 4 times daily using a cotton-tip applicator (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35080090','lexi-content-ref-10328192','lexi-content-ref-8077892','lexi-content-ref-26556433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35080090','lexi-content-ref-10328192','lexi-content-ref-8077892','lexi-content-ref-26556433'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a1f8db4-ca13-423c-bf8f-55b088d2fd85">Proctitis due to radiation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proctitis due to radiation (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: For mild persistent rectal pain, tenesmus, or bleeding. Regimen details (eg, volume administered, duration of enema retention) may vary based on institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12297939','lexi-content-ref-1670631','lexi-content-ref-10235606','lexi-content-ref-Oneill.1','lexi-content-ref-Royal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12297939','lexi-content-ref-1670631','lexi-content-ref-10235606','lexi-content-ref-Oneill.1','lexi-content-ref-Royal.1'])">Ref</a></span>). An <b>example regimen</b> is provided:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal:</b> Retention enema: 2 g (tablets or suspension) dissolved in 20 mL water twice daily for at least 4 weeks or until resolution of symptoms; retain each enema for as long as possible or at least 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12297939','lexi-content-ref-1670631','lexi-content-ref-10235606','lexi-content-ref-Oneill.1','lexi-content-ref-Royal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12297939','lexi-content-ref-1670631','lexi-content-ref-10235606','lexi-content-ref-Oneill.1','lexi-content-ref-Royal.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce3d388e-fd97-46fb-aa7d-a55ad4b0b74c">Upper GI toxicity following radiation therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper GI toxicity following radiation therapy (adjunctive agent) (off-label use): Oral:</b> Suspension: 1 g four times daily generally for 2 weeks postprocedure as a component of a combination regimen (eg, with antisecretory agent[s], analgesic[s], and/or local anesthetic as needed). Optimal regimen has not been established; refer to published and institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28407278','lexi-content-ref-Czito.1','lexi-content-ref-18494131','lexi-content-ref-27956164','lexi-content-ref-24668102','lexi-content-ref-21209124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28407278','lexi-content-ref-Czito.1','lexi-content-ref-18494131','lexi-content-ref-27956164','lexi-content-ref-24668102','lexi-content-ref-21209124'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991794"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, rectal: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (minimal systemic absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: No dosage adjustment necessary. However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (minimal systemic absorption): No dosage adjustment necessary. However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (minimal systemic absorption): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> No dosage adjustment necessary. However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary. However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11261535','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988991"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F223524"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Use with caution; initiate at low end of dosage range.</p></div>
<div class="block dop drugH1Div" id="F223543"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12811" href="/d/html/12811.html" rel="external">see "Sucralfate: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="45122f7e-0f66-41d8-80e6-643b990d4646">Peptic ulcer disease, adjunct therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease, adjunct therapy:</b> Limited data available: Infants, Children, and Adolescents: Oral: 40 to 80 mg/kg/day divided every 6 hours. Maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-Nelson.1996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-Nelson.1996'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2881f1c-7ec3-4b33-b804-1bb009c34b08">Esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophagitis:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2735338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2735338'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children &lt;6 years: Oral: 500 mg/dose four times daily</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years: Oral: 1,000 mg/dose four times daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing from a prospective trial of 75 patients (age range: 3 months to 13 years) who received sucralfate tablets (n=25), sucralfate suspension (n=25), or cimetidine (n=25) for reflux esophagitis. At the end of 8 weeks, 68% of patients receiving sucralfate tablet, 92% of patients receiving sucralfate suspension, and 79% of patients receiving cimetidine were asymptomatic. Sucralfate was well tolerated.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160188"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Aluminum salt is minimally absorbed (&lt;5%); however, may accumulate in renal failure; use with caution in patients with chronic renal failure.</p></div>
<div class="block dohp drugH1Div" id="F51160189"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F223491"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Constipation (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, back pain, bezoar formation, bronchospasm, diarrhea, dizziness, drowsiness, dyspepsia, facial edema, flatulence, gastric distress, headache, hyperglycemia, hypersensitivity reaction, insomnia, laryngeal edema, mouth edema, nausea, pharyngeal edema, pruritus, pulmonary edema, skin rash, vertigo, vomiting, xerostomia</p></div>
<div class="block coi drugH1Div" id="F223504"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to sucralfate or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F223488"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Hyperglycemia has been reported with sucralfate suspension in patients with diabetes; monitor glycemia closely; adjustment of antidiabetic treatment may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duodenal ulceration: Because sucralfate acts locally at the ulcer, successful therapy with sucralfate should not be expected to alter the posthealing frequency of recurrence or the severity of duodenal ulceration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with advanced kidney impairment. Sucralfate is an aluminum complex; small amounts of aluminum are absorbed following oral administration. Excretion of aluminum may be decreased in patients with advanced kidney impairment or on dialysis, increasing the risk of aluminum accumulation and toxicity (eg, aluminum osteodystrophy, osteomalacia, and encephalopathy).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tablets: Use with caution in patients with conditions that may impair swallowing (eg, recent or prolonged intubation, tracheostomy, dysphagia, history of aspiration) or other conditions that may alter gag/cough reflexes, or diminish oropharyngeal coordination or motility; aspiration with accompanying respiratory complications has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Administer sucralfate by oral or rectal route only; fatal complications, including cerebral and pulmonary emboli, have been reported with inadvertent IV administration of sucralfate.</p></div>
<div class="block foc drugH1Div" id="F223498"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carafate: 1 g/10 mL (420 mL) [contains fd&amp;c red #40 (allura red ac dye), methylparaben, sorbitol; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/10 mL (10 mL, 414 mL, 420 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carafate: 1 g [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g</p></div>
<div class="block geq drugH1Div" id="F223484"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F223506"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Carafate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $0.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Sucralfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $0.86 - $1.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Carafate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $5.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sucralfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $0.38 - $4.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868304"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sulcrate Plus: 200 mg/mL (500 mL) [contains methylparaben sodium, propylparaben sodium]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cytogard: 1 g</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sulcrate: 1 g</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g</p></div>
<div class="block adm drugH1Div" id="F223501"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b>Administer on an empty stomach. Shake suspension well before use. Do not administer antacids within 30 minutes of administration of sucralfate. In general, separate administration of other oral medications and sucralfate by at least 2 hours; consult drug interactions database for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal</b>: Enema: Prepare for immediate use. Dissolve 2 sucralfate 1 g tablets in 20 mL of warm water, or 10 mL sucralfate suspension (1 g per 5 mL) in 10 to 20 mL of warm, not hot, water. Fill delivery apparatus (ie, enema bag, Toomey syringe, or 60 mL catheter tip syringe with 14F self-retaining foley catheter) with selected preparation and apply lubricant to tip. Insert tip 1 ½ inches into the rectum. Allow mixture to enter into the rectum and retain in the rectum for as long as possible or at least 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12297939','lexi-content-ref-1670631','lexi-content-ref-10630828','lexi-content-ref-Oneill.1','lexi-content-ref-Royal.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12297939','lexi-content-ref-1670631','lexi-content-ref-10630828','lexi-content-ref-Oneill.1','lexi-content-ref-Royal.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613885"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach 1 hour before meals and at bedtime; tablet may be broken or dissolved in water before ingestion; do not administer antacids within 30 minutes of administration; shake suspension well before use. In general, separate administration of other oral medications and sucralfate by at least 2 hours; consult drug interactions database for additional information.</p></div>
<div class="block use drugH1Div" id="F223500"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Duodenal ulcer:</b> Short-term (≤8 weeks) treatment of active duodenal ulcers; maintenance therapy for duodenal ulcers (tablets only).</p></div>
<div class="block off-label drugH1Div" id="F56882411"><span class="drugH1">Use: Off-Label: Adult</span><p>Gastroesophageal reflux disease in pregnancy; Marginal (anastomotic) ulceration after bariatric surgery; Oral ulcers, simple recurrent stomatitis and ulcers associated with Behçet disease; Proctitis due to radiation; Upper GI toxicity following radiation therapy</p></div>
<div class="block mst drugH1Div" id="F223573"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sucralfate may be confused with salsalate</p>
<p style="text-indent:-2em;margin-left:4em;">Carafate may be confused with Cafergot</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">For oral or rectal administration only. Fatal pulmonary or cerebral embolism has been reported following inadvertent IV administration of sucralfate.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300087"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F223493"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May diminish the therapeutic effect of Sucralfate. Management: Consider separating the administration of antacids and sucralfate by at least 30 minutes.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir.  Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholic Acid: Sucralfate may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of aluminum-containing products such as sucralfate to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Sucralfate may decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin.  Management: Administer digoxin at least 2 hours before sucralfate. Concomitant administration should be avoided. Monitor for decreased digoxin levels/effects with initiation of sucralfate therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Sucralfate may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after sucralfate. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: Sucralfate may decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide.  Management: Separate orally administered furosemide from sucralfate administration by at least 2 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Sucralfate may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Sucralfate may decrease the absorption of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Sucralfate may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Sucralfate may decrease the serum concentration of Levothyroxine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum may be increased. Sucralfate may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, sucralfate may impair the absorption of fluoride. Management: Avoid administration of aluminum-containing products, such as sucralfate, within at least 1-2 hours of fluoride administration. In patients with severe renal dysfunction, consider avoiding this combination altogether.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Sucralfate may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Sucralfate may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate administration. Administering oral phosphate supplements at least 2 hours before sucralfate may reduce the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Sucralfate may decrease the serum concentration of QuiNIDine. Specifically, sucralfate may decrease the absorption of quinidine.  Management: Administer quinidine at least 2 hours before sucralfate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Sucralfate may decrease the serum concentration of Quinolones.  Management: Avoid concurrent administration of quinolones and sucralfate to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Sucralfate may decrease the serum concentration of Sulpiride.  Management: Separate administration of sucralfate and sulpiride by at least 2 hours in order to minimize the impact of sucralfate on sulpiride absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Sucralfate may decrease the absorption of Tetracyclines.  Management: Administer most tetracycline derivatives at least 2 hours prior to sucralfate in order to minimize the impact of this interaction. Administer oral omadacycline 4 hours prior to sucralfate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Management: Consider avoiding chronic use of aluminum and aluminum-containing products, such as sucralfate, in patients who are also taking active vitamin D analogs. If combined, monitor for signs and symptoms of aluminum-related toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Sucralfate may diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists.  Management: Monitor for decreased vitamin K antagonist effects (eg, decreased INR, thrombosis) when these agents are combined and consider administering vitamin K antagonists at least 2 hours before sucralfate to minimize this interaction.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F223507"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sucralfate is only minimally absorbed following oral administration. Based on available data, sucralfate does not appear to increase the risk of adverse fetal events when used during the first trimester. Sucralfate is considered acceptable for use in pregnancy (Dağlı 2017; Gomes 2018; Thélin 2020).</p></div>
<div class="block brc drugH1Div" id="F16571276"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sucralfate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate is only minimally absorbed following oral administration. Although the manufacturer recommends that caution be exercised when administering sucralfate to breastfeeding women, use is considered acceptable (Dağlı 2017).</p></div>
<div class="block dic drugH1Div" id="F223508"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with water on an empty stomach.</p></div>
<div class="block mop drugH1Div" id="F50641652"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood glucose levels (in diabetic patients receiving oral suspension).</p></div>
<div class="block pha drugH1Div" id="F223487"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Forms a complex by binding with positively charged proteins in exudates, forming a viscous paste-like, adhesive substance. This selectively forms a protective coating that acts locally to protect the gastric lining against peptic acid, pepsin, and bile salts. </p></div>
<div class="block phk drugH1Div" id="F223503"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Paste formation and ulcer adhesion: 1 to 2 hours; acid neutralizing capacity: ~14 to 16 mEq/1 g dose of sucralfate</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal from GI tract</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Acts locally at ulcer sites; unbound in GI tract to aluminum and sucrose octasulfate</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: None</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (small amounts of sulfated disaccharide)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F223509"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-sucralfate | Gastrofait | Ulsaheal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Antepsin | Gastromed | Netunal | Sucralfato denver farma | Sucralfort | Sucralmax | Vastacid</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sucralan | Sucralbene | Sucralfat genericon | Sucralstad | Sucramed | Ulcogant</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Carafate | Ulcyte</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Antepsin | Gastalfet | Gastonic | Gestalfet | Sucrol | Ucrafate | Ulfate | Ulsanic</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ulcogant</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Ulcar</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Sucralfat | Venter</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ulcogant</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Sucrafil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Gastrocol | Mulcatel | Sucralmax | Sulcran</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Di xian | Hua di | Shu ke fei | Sucrate | Wei xiao</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Albisan | Alsucral | Antepsin | Dip | Sucralfato | Sugastrin | Treceptan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alsucral | Sucralan | Ulcogant | Venter</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sucrabest | Sucralfat | Sucraphil | Ulcogant</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Etisucral | Eurogastro | Sucrassyl | Tenofed | Ulcogant</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ciprid | Dip | Sucralgastric | Ulcon | Yastrep</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Antepsin | Sucrabest | Venter</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Gastrofait | Sucrofilmpan | Ulcar</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tiblex | Urbal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alsucral | Antepsin | Succosa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Keal | Sucralfate rpg | Sucralfate teva | Ulcar</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Antepsin | Sucralfate kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dolisec | Peptonorm</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-sucralfate | Sucari | Sucralfat Ratiopharm 1000 | Sucway | Ulsanic</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alusulin | Ulcogant | Venter</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Benofat | Dopepsa | Eficap | Episan | Kalpepsa | Lanpepsa | Lipepsa | Mucifat | Mucogard | Musin | Neciblok | Nucral | Pepco | Peptovell | Profat | Propepsa | Taxilan | Ulcron | Ulcumaag | Ulfat | Ulsafate | Ulsanic | Ulsicral | Ulsidex</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Antepsin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ulsanic</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acicrol | Ancool sf | Cral | Filcer | Gistress | Lenocarb s | Mac S | Macralfate | Mucobind | Pepsigard | Qpfate | Rab sf | Sft | Sigral | Skf | Sparacid | Stalfate | Sucfate | Sucrace | Sucracid | Sucraday | Sucrafil | Sucragel | Sucral | Sucralcoat | Sucramal | Sucramax | Sucramed | Sucrazen | Sufate | Sufrate | Suwin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Antepsin | Crafilm | Sucrager | Sucralfato | Sucralfin | Sucramal | Sucrate | Sucroril | Sugast</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Gastrofait</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Altsamin taiyo | Alusajust yoshindo | Ulcerlmin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sucramed | Ulcermin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Gastrofait</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ulcar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alsucral | Gastrofait | Ulcogant | Venter</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Keal | Sucrabest | Ulcogant</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alsucral | Antepsin | Peptonorm | Sucrabest | Sucralfat | Sucralfat genericon | Ulcogant | Venter</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Keal | Sugast | Ulcar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alivoato | Alomoon | Apo-lato | Discral | Duodenel | Grismar | Metixane | Mogamigue | Rextrem | Sucralfato | Ulsicral | Unival</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alsucral | Apo-sucralfate | Ulcertec | Ulsanic</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Sucragel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Sucralfaat | Sucralfaat gf | Sucralfaat Ratiopharm | Ulcogant</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Antepsin | Sucralan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Carafate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Didunal | Kalfrex | Sucragant | Sucralex | Sucralflam | Sucralit | Sucralmax | Sucrate | Sucraxol | Sufacrato | Sulcran | Ulcoflux | Ulcogant</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Iselpin | Sucragen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cidifen | Crafilm | Cralfate | Cralsim | Fynkofate | Grasfate | Lacrate | Medgel | Orafate | Radifate | Ralfate | Sate | Sofet | Sucfate | Sucmed | Sucradale | Sucrafate | Sucralmed | Sucrasel | Surate | Surlka | Ulcafate | Ulcerate | Ulcercure | Ulcoat | Ulcocid | Ulcode | Ulfate | Ulsanic</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ancrusal | Ulcogant | Ulgastran | Venter</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carafate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Calfate | Cinebil | Sucralfato | Sucralum | Ulcermin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acipront | Kotric | Sucral | Sulfitriec</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Gastrofait | Venter</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Venter</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-sucralfate | Gastrofait | Ulsaheal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Andapsin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alsucral | Ulcertec</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ulcogant | Venter</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Scf | Sucrafen | Sucral | Sucratab | Ulcefate | Ulcrafate | Ulsanic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ulcar | Ulcefix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Antepsin | Karfat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anwenin | Aso | Bigast | Salet | Scrat | Sucafate | Sucra | Sucral | Sucrate | Sucway | Suicrate | Suwel | Ulcegban | Ulcerban | Ulcerfate | Ulsanic | Ulsate | Weizip</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alsucral | Aluzulin | Sucralfat kmp | Venter | Ventor</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alusac | Cralfate | Historal | Sucralfato | Unaltec</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Digifal | Dip | Exinol | Sucralfato | Ulciram | Ulcon | Ulcraf</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Sarufone</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ulcefate | Ulcetic | Ulsanic</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35080090">
<a name="35080090"></a>Abtahi-Naeini B, Saffaei A, Sabzghabaee AM, et al. Topical sucralfate for treatment of mucocutaneous conditions: a systematic review on clinical evidences. <i>Dermatol Ther</i>. 2022;35(4):e15334. doi:10.1111/dth.15334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/35080090/pubmed" id="35080090" target="_blank">35080090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Algozzine.1">
<a name="Algozzine.1"></a>Algozzine GJ, Hill G, Scoggins WG, et al. Sucralfate Bezoar. <i>N Engl J Med</i>. 1983;309(22):1387.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10328192">
<a name="10328192"></a>Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. <i>Arch Dermatol</i>. 1999;135(5):529-532. doi:10.1001/archderm.135.5.529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/10328192/pubmed" id="10328192" target="_blank">10328192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apo-Sucralfate.1">
<a name="Apo-Sucralfate.1"></a>Apo-Sucralfate (sucralfate) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2735338">
<a name="2735338"></a>Argüelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. <i>Am J Med</i>. 1989;86(6A):73-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/2735338/pubmed" id="2735338" target="_blank">2735338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29556889">
<a name="29556889"></a>Barola S, Fayad L, Hill C, et al. Endoscopic management of recalcitrant marginal ulcers by covering the ulcer bed. <i>Obes Surg</i>. 2018;28(8):2252-2260. doi:10.1007/s11695-018-3162-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/29556889/pubmed" id="29556889" target="_blank">29556889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brice.1">
<a name="Brice.1"></a>Brice S, Lodi G . Recurrent aphthous stomatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carafate.1">
<a name="Carafate.1"></a>Carafate (sucralfate) suspension [prescribing information]. Madison, NJ: Allergan USA Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carafate.2">
<a name="Carafate.2"></a>Carafate (sucralfate) tablets [prescribing information]. Madison, NJ: Allergan USA, Inc; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12639084">
<a name="12639084"></a>Collard HR, Saint S, and Matthay MA, “Prevention of Ventilator-Associated Pneumonia: An Evidence-Based Systematic Review,” <i>Ann Intern Med</i>, 2003, 138(6):494-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/12639084/pubmed" id="12639084" target="_blank">12639084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9504939">
<a name="9504939"></a>Cook D, Guyatt G, Marshall J, et al, “A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation. Canadian Critical Care Trials Group,” <i>N Engl J Med</i>, 1998, 338(12):791-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/9504939/pubmed" id="9504939" target="_blank">9504939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Czito.1">
<a name="Czito.1"></a>Czito BG, Meyer JJ, Willett CG. Overview of gastrointestinal toxicity of radiation therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29199169">
<a name="29199169"></a>Dağlı Ü, Kalkan İH. Treatment of reflux disease during pregnancy and lactation. <i>Turk J Gastroenterol</i>. 2017;28(Suppl 1):S53-S56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/29199169/pubmed" id="29199169" target="_blank">29199169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16925380">
<a name="16925380"></a>Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery. <i>Surg Obes Relat Dis</i>. 2006;2(4):455-459. doi:10.1016/j.soard.2006.03.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/16925380/pubmed" id="16925380" target="_blank">16925380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29991883">
<a name="29991883"></a>Gomes CF, Sousa M, Lourenço I, Martins D, Torres J. Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know?. <i>Ann Gastroenterol</i>. 2018;31(4):385‐394. doi:10.20524/aog.2018.0264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/29991883/pubmed" id="29991883" target="_blank">29991883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18494131">
<a name="18494131"></a>Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. <i>Endoscopy</i>. 2008;40(5):359-369. doi:10.1055/s-2007-995567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/18494131/pubmed" id="18494131" target="_blank">18494131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12297939">
<a name="12297939"></a>Gul YA, Prasannan S, Jabar FM, Shaker AR, Moissinac K. Pharmacotherapy for chronic hemorrhagic radiation proctitis. <i>World J Surg</i>. 2002;26(12):1499-1502. doi:10.1007/s00268-002-6529-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/12297939/pubmed" id="12297939" target="_blank">12297939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11261535">
<a name="11261535"></a>Hemstreet BA. Use of sucralfate in renal failure. <i>Ann Pharmacother</i>. 2001;35(3):360-364. doi:10.1345/aph.10117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/11261535/pubmed" id="11261535" target="_blank">11261535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34807007">
<a name="34807007"></a>Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. <i>Am J Gastroenterol</i>. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/34807007/pubmed" id="34807007" target="_blank">34807007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, et al, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1670631">
<a name="1670631"></a>Kochhar R, Patel F, Dhar A, et al. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. <i>Dig Dis Sci</i>. 1991;36(1):103-107. doi:10.1007/BF01300096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/1670631/pubmed" id="1670631" target="_blank">1670631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10235606">
<a name="10235606"></a>Kochhar R, Sriram PV, Sharma SC, Goel RC, Patel F. Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension. <i>Dig Dis Sci</i>. 1999;44(5):973-978. doi:10.1023/a:1026612731210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/10235606/pubmed" id="10235606" target="_blank">10235606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9060567">
<a name="9060567"></a>Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III Controlled Evaluation of Sucralfate to Alleviate Stomatitis in Patients Receiving Fluorouracil-Based Chemotherapy. <i>J Clin Oncol</i>. 1997;15(3):1235-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/9060567/pubmed" id="9060567" target="_blank">9060567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10630828">
<a name="10630828"></a>Melko GP, Turco TF, Phelan TF, Sauers NM. Treatment of radiation-induced proctitis with sucralfate enemas. <i>Ann Pharmacother</i>. 1999;33(12):1274-1276. doi:10.1345/aph.19065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/10630828/pubmed" id="10630828" target="_blank">10630828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oneill.1">
<a name="Oneill.1"></a>O'Neill T; University of Michigan Health - Michigan Medicine. Carafate (sucralfate) enemas. <a href="https://www.med.umich.edu/1libr/MBCP/CarafateEnemas.pdf" target="_blank">https://www.med.umich.edu/1libr/MBCP/CarafateEnemas.pdf</a>. Accessed June 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8181371">
<a name="8181371"></a>Overdahl MC, Wewers MD. Acute Occlusion of a Mainstem Bronchus by a Rapidly Expanding Foreign Body. <i>Chest</i>. 1994;105(5):1600-1602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/8181371/pubmed" id="8181371" target="_blank">8181371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16863545">
<a name="16863545"></a>Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. <i>Am J Gastroenterol</i>. 2006;101(7):1449-1457. doi:10.1111/j.1572-0241.2006.00635.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/16863545/pubmed" id="16863545" target="_blank">16863545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27956164">
<a name="27956164"></a>Phoa KN, Rosmolen WD, Weusten BLAM, et al; SURF investigators. The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial). <i>Gastrointest Endosc</i>. 2017;86(1):120e2-129.e2. doi:10.1016/j.gie.2016.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/27956164/pubmed" id="27956164" target="_blank">27956164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24668102">
<a name="24668102"></a>Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. <i>JAMA</i>. 2014;311(12):1209-1217. doi:10.1001/jama.2014.2511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/24668102/pubmed" id="24668102" target="_blank">24668102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ranchet.1">
<a name="Ranchet.1"></a>Ranchet G, Gangemi O, Petrone M. Sucralfate in the treatment of pregnancy pyrosis. Il Sucralfato nel trattamento della pirosi gravidica. <i>Giorn It Ost Gin.</i> 1990;12(1):91-96.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17514403">
<a name="17514403"></a>Rasmussen JJ, Fuller W, Ali MR. Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients. <i>Surg Endosc</i>. 2007;21(7):1090-1094. doi:10.1007/s00464-007-9285-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/17514403/pubmed" id="17514403" target="_blank">17514403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8077892">
<a name="8077892"></a>Rattan J, Schneider M, Arber N, Gorsky M, Dayan D. Sucralfate suspension as a treatment of recurrent aphthous stomatitis. <i>J Intern Med</i>. 1994;236(3):341-343. doi:10.1111/j.1365-2796.1994.tb00805.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/8077892/pubmed" id="8077892" target="_blank">8077892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16225482">
<a name="16225482"></a>Richter JE. Review article: the management of heartburn in pregnancy. <i>Aliment Pharmacol Ther</i>. 2005;22(9):749-757. doi:10.1111/j.1365-2036.2005.02654.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/16225482/pubmed" id="16225482" target="_blank">16225482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2742249">
<a name="2742249"></a>Robertson JA, Salusky IB, Goodman WG, et al. Sucralfate, Intestinal Aluminum Absorption, and Aluminum Toxicity in a Patient on Dialysis. <i>Ann Intern Med</i>. 1989;111(2):179-181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/2742249/pubmed" id="2742249" target="_blank">2742249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Royal.1">
<a name="Royal.1"></a>Royal United Hospitals Bath NHS Foundation Trust. Sucralfate enemas. https://www.ruh.nhs.uk/patients/services/gastroenterology/documents/GAS008_Sucralfate_Enema_Factsheet.pdf. Published February 2022. Accessed June 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28407278">
<a name="28407278"></a>Sangro B, Martínez-Urbistondo D, Bester L, et al. Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. <i>Hepatology</i>. 2017;66(3):969-982. doi:10.1002/hep.29207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/28407278/pubmed" id="28407278" target="_blank">28407278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28809386">
<a name="28809386"></a>Schulman AR, Thompson CC. Complications of bariatric surgery: what you can expect to see in your GI practice. <i>Am J Gastroenterol</i>. 2017;112(11):1640-1655. doi:10.1038/ajg.2017.241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/28809386/pubmed" id="28809386" target="_blank">28809386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26556433">
<a name="26556433"></a>Soylu Özler G, Okuyucu Ş, Akoğlu E. The efficacy of sucralfate and chlorhexidine as an oral rinse in patients with recurrent aphthous stomatitis. <i>Adv Med</i>. 2014;2014:986203. doi:10.1155/2014/986203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/26556433/pubmed" id="26556433" target="_blank">26556433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24347350">
<a name="24347350"></a>Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA, Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric bypass: results of an international survey. <i>Obes Surg</i>. 2014;24(5):741-746. doi:10.1007/s11695-013-1152-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/24347350/pubmed" id="24347350" target="_blank">24347350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sulcrate.1">
<a name="Sulcrate.1"></a>Sulcrate and Sulcrate Suspension Plus (sucralfate) [product monograph]. Mont-St-Hilaire, Quebec, Canada: Aptalis Pharma Canada Inc; September 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31950535">
<a name="31950535"></a>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. <i>Aliment Pharmacol Ther</i>. 2020;51(4):421‐434. doi:10.1111/apt.15611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/31950535/pubmed" id="31950535" target="_blank">31950535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21209124">
<a name="21209124"></a>van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. <i>Gut</i>. 2011;60(6):765-773. doi:10.1136/gut.2010.229310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sucralfate-drug-information/abstract-text/21209124/pubmed" id="21209124" target="_blank">21209124</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9953 Version 403.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
